Biotech ETFs Strengthen as Bristol Myers Squibb Buys Turning Point
Turning Point Stock Doubles After Bristol Myers Announces Takeover
Why Bristol-Myers Squibb (BMY) Is Buying Turning Point Therapeutics (TPTX) In A $4.1 Billion Deal
Turning Point Therapeutics stock more than doubles after Bristol Myers buyout deal valuing company at $3.8 billion
Best Biotech Stocks To Buy Now? 5 To Know
FDA Clears Turning Point's IND For Elzovantinib + Aumolertinib Combo Regime In Lung Cancer Setting
Turning Point's RET Inhibitor Candidate Shows Tolerable Safety Profile, Early Signals Of Activity In Solid Tumor Settings